Adjunctive recombinant human parathyroid hormone agents for the treatment of medication-related osteonecrosis of the jaw: a report of three cases

Soo Young Choi, Dami Yoon, Kang Min Kim, Sun Jong Kim, Heon Young Kim, Jin Woo Kim, Jung Hyun Park

Research output: Contribution to journalArticlepeer-review

Abstract

Teriparatide has been effective in treating people diagnosed with medication-related osteonecrosis of the jaw (MRONJ). However, its efficacy is not well established to be accepted as a standard of care. The objective of this paper was to investigate the efficacy of recombinant human parathyroid hormone for the treatment of MRONJ. We report three cases of MRONJ patients with osteoporosis as the primary disease who were treated with a teriparatide agent along with other adjunctive measures. Each patient was administered a teriparatide injection subcutaneously for 16 weeks, 36 weeks, or 60 weeks. Surgical intervention including partial resection, sequestrectomy, decortication, and saucerization took place during the teriparatide administration. Complete lesion resolution was identified clinically and radiographically in all three patients. In patients diagnosed with MRONJ, teriparatide therapy is an efficacious and safe therapeutic option to improve healing of bone lesions. These findings demonstrate that teriparatide in combination with another therapy, especially bone morphogenetic protein, platelet-rich fibrin, or antibiotic therapy, can be an effective protocol for MRONJ.

Original languageEnglish
Pages (from-to)103-109
Number of pages7
JournalJournal of the Korean Association of Oral and Maxillofacial Surgeons
Volume50
Issue number2
DOIs
StatePublished - 2024

Bibliographical note

Publisher Copyright:
© 2024 The Korean Association of Oral and Maxillofacial Surgeons.

Keywords

  • Bisphosphonate-associated osteonecrosis of the jaw
  • Forteo
  • Human parathyroid hormone (1-34)
  • Osteoporosis
  • Teriparatide

Fingerprint

Dive into the research topics of 'Adjunctive recombinant human parathyroid hormone agents for the treatment of medication-related osteonecrosis of the jaw: a report of three cases'. Together they form a unique fingerprint.

Cite this